Alexey V. Voitov

Alexey V. Voitov

Auto-generated profile, based on publicly available information

Alexey V. Voitov

Meshalkin National Medical Research Center

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2015 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
AOAlexander Omelchenko
Alexander Omelchenko
YGYuriy Gorbatykh
Yuriy Gorbatykh
AVAlexey Voitov
Alexey Voitov
GZGregory Zaitsev
Gregory Zaitsev
ABAlexander V. Bogachev-Prokophiev
Alexander V. Bogachev-Prokophiev
AKAlexander Karaskov
Alexander Karaskov
OBJECTIVES To present and share our experience in perventricular device closure of ventricular septal defects in patients less than 1 year old. METHODS From 2012–2014, 51 patients less than 1 year old with ventricular septal defects were operated on with minimally invasive transthoracic device closure under the guidance of transoesophageal echocardiography (TOE) without cardiopulmonary bypass (CBP). The median age at operation was 8.0 ± 2.5 months and the mean body weight was 7.9 ± 3.4 kg; 7.3% (5) of patients had a weight less than 5 kg. The Qp/Qs ratio was 1.9 ± 0.4. The ventricular septal defect size ranged from 3 to 9 mm; the mean diameter was 5.7 ± 1.6 mm; 27.4% (14) of defects were subaortic, 66.7% (34) perimembranous and 5.9% (3) were muscular. For defect closure, we used a ventricular septal defect occlusion device (Lepu Medical Technology Co., Ltd, Beijing, China) through a 3-cm skin incision in the lower third of the sternum. RESULTS The procedural success rate was 96.1% and there were 2 patients who were converted to open-heart surgery (3.9%) during procedures. The operation time ‘skin to skin’ was 55.9 ± 41.0 (40) min; 48.8% of cases were less than 40 min. Intensive care unit stay was 16.5 ± 9.4 (18) h; ventilation time was 3.2 ± 3.5 (2) h; all patients did not require inotropic support, blood transfusion and analgesia. Of the total, 7.8% (4) of patients had residual shunt of not more than 1 mm; there were no atrioventricular blocks, rhythm disturbances or other types of major complications in the early postoperative period. Length of hospital stay was 5.6 ± 3.2 days. The mean follow-up was 18.7 ± 10.1. Residual shunts, conduction disturbances or valve complications were not observed in any patients. CONCLUSIONS Perventricular device closure of ventricular septal defects showed safety and high efficiency in patients less than 1 year of age, compared with conventional surgical repair with cardiopulmonary bypass, and provided a short period of rehabilitation and excellent cosmetic result.

10 February 2017 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
AVAlexey Voitov
Alexey Voitov
AOAlexander Omelchenko
Alexander Omelchenko
YGYuriy Gorbatykh
Yuriy Gorbatykh
GZGregory Zaitsev
Gregory Zaitsev
AAAlexey Arkhipov
Alexey Arkhipov
AKAlexander Karaskov
Alexander Karaskov
OBJECTIVES: Perventricular device closure (PVDC) of ventricular septal defects (VSDs) has demonstrated excellent clinical results. However, no prospective studies have compared PVDC with the conventional approach (CA). METHODS: Between June 2012 and August 2014, 640 consecutive patients with isolated VSD were enrolled in the study, and randomized into the PVDC group (n = 320) and the CA group (n = 320). The mean ages were 36.2 (10; 36) months and 36.2 (10; 36) months, respectively. The average weights were 13.9 (8.1; 15.0) kg and 14.5 (6.9; 13.8) kg, respectively. The mean follow-up was 24.9 (standard deviation 1.8) months. RESULTS: No early or late deaths occurred in either group. The procedural success rate reached 96.6% in the PVDC group, with a 3.4% conversion rate to CA. Mean procedure time was 56.9 (30; 70) min in the PVDC group and 162 (120; 180) min in the CA group (P = 0.000). Thirteen (3.9%) patients in the CA group and only 4 (1.3%) in the PVDC group required postoperative blood transfusion in the intensive care unit (P = 0.040). At the final follow-up, significantly more residual shunts were found in the CA group. No rhythm or conduction disorders occurred in any patient of either group. CONCLUSIONS: According to the mid-term follow-up results, PVDC has similar efficacy to CA for VSD closure. The off-pump PVDC technique reduces blood product transfusion and the procedural time and minimizes surgical trauma while providing excellent cosmetic results.

14 February 2018 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
NNNataly Nichay
Nataly Nichay
IZIrina Y Zhuravleva
Irina Y Zhuravleva
YKYuriy Yu Kulyabin
Yuriy Yu Kulyabin
TTTatyana P Timchenko
Tatyana P Timchenko
AVAlexey V Voitov
Alexey V Voitov
AKAlexander M Karaskov
Alexander M Karaskov
In this study, we aimed to determine the incidence of reintervention and calcification of xenografts in paediatric patients who underwent placement of the right ventricle-to-pulmonary artery valved conduits. We retrospectively analysed clinical data of paediatric patients (1 day–18 years) who underwent right ventricular outflow tract reconstruction using xenograft from 2000 to 2016 at a single centre. A total of 301 patients underwent the placement of 337 xenografts, including glutaraldehyde-treated bovine jugular vein (n = 171, 50.7%), glutaraldehyde-treated bovine pericardial valved conduit (n = 75, 22.3%), diepoxy-treated porcine aortic conduit (n = 58, 17.2%) and diepoxy-treated bovine pericardial valved conduit (DE-PVC) (n = 33, 9.8%). There were 284 (84.3%) primary implantations and 53 (15.7%) reimplantations. The median follow-up was 4.2 years (range 1.5 months–14.5 years). The multivariate regression analysis did not reveal statistically significant associations of the first reintervention with the type of xenograft (P = 0.78). At reintervention, calcification of the wall and/or cusps was the main cause of conduit dysfunction in 66.4% of cases. On the basis of the multivariate Cox regression analysis, xenograft types were significant predictors of reintervention caused by conduit calcification (P = 0.012). The diepoxy-treated porcine aortic conduit group had the risk of calcification 3 times higher than the glutaraldehyde-treated bovine jugular vein group (P < 0.001).The glutaraldehyde-treated bovine pericardial valved conduit and diepoxy-treated bovine pericardial valved conduit groups had the risk of calcification comparable with the glutaraldehyde-treated bovine jugular vein group in multivariate proportional hazards model (P = 0.36 and P = 0.59, respectively). We have not revealed significant difference in the freedom from first reintervention among types of conduit. Calcification leading to the conduit dysfunction was present in all groups; however, diepoxy-treated porcine aortic conduits demonstrated suboptimal results in terms of calcification at follow-up.

15 January 2018 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
IZIrina Y Zhuravleva
Irina Y Zhuravleva
NNNataliya R Nichay
Nataliya R Nichay
YKYuriy Yu Kulyabin
Yuriy Yu Kulyabin
TTTatyana P Timchenko
Tatyana P Timchenko
AKAlexander A Korobeinikov
Alexander A Korobeinikov
AKAlexander M Karaskov
Alexander M Karaskov
The development of calcification-resistant bioprosthetic materials is a very important challenge for paediatric surgery. The subcutaneous implantation in rats is the well-known first-stage model for this kind of research. Using this model, we aimed to compare calcification of the porcine aortic wall and bovine pericardium and jugular vein wall cross-linked with glutaraldehyde (GA) and ethylene glycol diglycidyl ether (DE). We also determined the efficacy of DE-preserved tissue modification with 2-(2-carboxyethylamino)ethylidene-1,1-bisphosphonic acid (CEABA). Three groups of each biomaterial were evaluated: GA-treated, DE-treated and DE + CEABA-treated. The microstructure of non-implanted biomaterials was assessed by light microscopy after Picro Mallory staining; the phosphorus content of the DE and DE + CEABA samples was assessed by atomic emission spectrometry. Samples were implanted subcutaneously into young rats for 10 and 60 days. The explant end-point included quantitative calcification assessment by atomic absorption spectrophotometry and light microscopy examination after von Kossa staining. All GA-treated biomaterials had a high calcium-binding capacity (>100 μg/mg dry tissue). DE preservation decreased the vein wall and pericardium calcium content by 4- and 40-fold, respectively, but was ineffective for the aortic wall. The calculated CEABA content was almost equal in the vein wall and pericardium (17.7 and 18.5 μM/g) and slightly less in the aortic wall (15 μM/g) (P = 0.011). CEABA effectively reduced mineralization in the DE aortic wall and DE pericardium to 10.1 (7.8-21.1) and 0.95 (0.57-1.38) μg/mg but had no effect in the DE vein wall. Mineralization in the GA- and DE-treated aortic and vein walls was predominantly associated with elastin. CEABA modification decreased elastin calcification but did not block it completely. Each xenogeneic material requires individual anticalcification strategy. DE + CEABA pretreatment demonstrates a high mineralization-blocking efficacy for the bovine pericardium and should be employed to further develop the paediatric pericardial conduit. Aortic wall calcification cannot be blocked completely using this strategy.

3 July 2020 in Patologiya krovoobrashcheniya i kardiokhirurgiya
Verified
Journal Article
Open access
PDF file
КРК. А. Рзаева
К. А. Рзаева
ISI. Soynov
I. Soynov
AGA. Gorbatykh
A. Gorbatykh
YKYuriy Yu Kulyabin
Yuriy Yu Kulyabin
AVA. Voitov
A. Voitov
ЮГЮ. Н. Горбатых
Ю. Н. Горбатых
Critical coarctation of the aorta in newborns usually presents with severe narrowing of the cavotricuspid isthmus and space adjacent to the arterial duct, limiting blood flow to the thoracic aorta. Patient survival depends on duct patency. Rapid deterioration and development of multiple organ failure usually result from spontaneous closure of the patent arterial duct. This deterioration is due in part to reduced renal perfusion and results in fluid and acid retention, causing heart failure and metabolic acidosis. This may be alleviated by the administration of intravenous prostaglandin E1, with a temporary improvement in distal aortic blood flow and the overall condition of the patient. Primary repair is associated with a high risk of unfavourable outcomes due to severe systemic outflow obstruction and multiple organ failure. Therefore, as a bridge to subsequent radical surgery, palliative stenting is the preferred method in newborns with critical aortic coarctation in the decompensated state.Received 16 January 2020. Revised 29 March 2020. Accepted 30 March 2020.Funding: The study did not have sponsorship.Conflict of interest: Authors declare no conflict of interest.Author contributionsConception and design: S.M. Ivantsov, A.V. Voitov, Yu.Yu. KulyabinDrafting the article: K.A. RzaevaCritical revision of the article: I.A. Soynov, A.V. Gorbatykh, Yu.N. Gorbatykh, A.V. Bogachev-ProkophievFinal approval of the version to be published: K.A. Rzaeva, I.A. Soynov, A.V. Gorbatykh, Yu.Yu. Kulyabin, A.V. Voitov, S.M. Ivantsov, Yu.N. Gorbatykh, A.V. Bogachev-Prokophiev

14 August 2017 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
YKYuriy Yu Kulyabin
Yuriy Yu Kulyabin
ISIlya A Soynov
Ilya A Soynov
AZAlexey V. Zubritskiy
Alexey V. Zubritskiy
AVAlexey V. Voitov
Alexey V. Voitov
NNNataliya R. Nichay
Nataliya R. Nichay
AKAlexander M. Karaskov
Alexander M. Karaskov
OBJECTIVES: This study aimed to assess mitral valve function after repair of ventricular septal defect (VSD) combined with mitral regurgitation (MR) in the mid-term follow-up period, to evaluate the clinical utility of simultaneous mitral valve repair (MVR). METHODS: From June 2005 to March 2014, 60 patients with VSD and MR underwent surgical treatment. After performing propensity score analysis (1:1) for the entire sample, 46 patients were selected and divided into 2 groups: those with VSD closure and MVR (VSD + MVR, 23 patients) and those with VSD closure without mitral valve intervention (VSD only, 23 patients). The follow-up period ranged from 12 to 48 months (median 32 months; interquartile range 28–40 months). RESULTS: There was no postoperative mortality in either group. There was no significant difference in the duration of the postoperative period between groups (ventilation time, P = 0.49; inotropic support, P = 0.50). Mean cardiopulmonary bypass time and aortic cross-clamping time were significantly longer in the ‘VSD + MVR’ group (cardiopulmonary bypass, P = 0.023; aortic cross-clamp, P < 0.001). There was no significant difference in regurgitation area (P = 0.30) and MR grade (P = 0.76) between groups postoperatively. There was no significant difference in freedom from MR ≥ 2+ between groups (log-rank test, P = 0.28). In the ‘VSD + MVR’ group, 12-, 36- and 42-month freedom from MR ≥ 2+ values were 100%, 59 ± 10.4% [95% confidence interval (CI) 36.1–76.2%] and 44 ± 15% (95% CI 15.8–69.7%), respectively, while in the ‘VSD only’ group, these values were 100%, 54.5 ± 10.6% (95% CI 32–72.3%) and 54.5 ± 10.6% (95% CI 30–72.3%), respectively. The only significant risk factor for recurrent MR ≥ 2+ during the follow-up period was mild residual MR in the early postoperative period (P = 0.037). CONCLUSIONS: In infants with VSD combined with MR, simultaneous MVR has no benefits simultaneous MVR provided no advantage over that of isolated VSD closure. We found that the presence of mild residual MR in the early postoperative period predisposes the development of MR ≥ 2+ in follow-up period.